
Neoadjuvant Niraparib Fails to Produce Substantial Pathologic Responses After Radical Prostatectomy in DDR-Deficient ...
Treatment with neoadjuvant niraparib (Zejula) prior to planned radical prostatectomy failed to generate complete or partial pathologic responses among patients with prostate cancer harboring heterogenous DNA damage repair (DDR) alterations, according to …